Boston Scientific (NYSE: BSX) on Friday announced it has European regulators' approval to sell its Spectra spinal cord stimulator (SCS) system in Europe.

A BSX news release announced the approval Friday morning, putting the potential European market at about 95 million patients. Chronic pain, which the Spectra system is designed to treat, affects one in five European adults, or 95 million between the ages of 15 and 64, according to the release.

Spectra is an implantable device that manages pain using electrical stimulus to the spinal cord, masking pain signals as they travel to the brain.